Replies to post #213972 on Biotech Values

[DewDiligence]

ENTA—Mavyret scripts for week ending 9/29/17 (from IMS)…

TRx: 493, +31% from prior week
NRx: 344, +29% from prior week

We are now 9 weeks into the US launch.

(As previously noted, Mavyret’s absolute script numbers reported by IMS are low because IMS misses much of the public sector of the HCV market that ABBV is targeting.)